Brought to you by:
-
chronic limb-threatening ischemia, CLI, CLTI, critical limb ischemia, LimFlow, PAD, percutaneous deep vein arterialization, VIVA
End-stage CLTI: Deep-vein arterialization procedure demonstrates amputation-free survival rate of 66% at six months
Six-month results from the PROMISE II trial of the LimFlow deep-vein arterialization system showed an overall amputation-free survival of 66%—“well above” the primary endpoint target of 54%, chief investigator Daniel Clair, MD, told the 2022 Vascular Interventional Advances (VIVA) meeting (Oct. 31–Nov. 3) in Las Vegas. The PROMISE II research team further demonstrated a limb…
-
Carotid disease, carotid endarterectomy, CEA, Midwestern Vascular Surgical Society, MVSS, TCAR, transfemoral carotid artery stenting
CEA, TCAR ‘continue to show superior outcomes’ to transfemoral stenting
Researchers led by a vascular team in Indianapolis found that carotid endarterectomy (CEA) remains the most-used strategy in carotid revascularization, with CEA and transcarotid artery revascularization (TCAR) showing decreased odds of stroke or death compared to transfemoral carotid artery stenting (TF-CAS). Those were among the main findings delivered by Hanaa Dakour Aridi, MD, an integrated…
-
DCB, IN.PACT Admiral, IN.PACT Admiral DCB, Medtronic, Surmodics, SurVeil, Surveil DCB, transcend, VIVA 2022
SurVeil DCB demonstrates sustained durability of safety, efficacy endpoints in TRANSCEND
In the TRANSCEND clinical trial, the SurVeil drug-coated balloon (DCB; Surmodics) demonstrated “excellent efficacy and safety” out to 24-month follow-up. This is according to Kenneth Rosenfield, MD, from Massachusetts General Hospital in Boston, who presented the new data at Vascular Interventional Advances (VIVA) 2022 (Oct. 31–Nov. 3) in Las Vegas. The TRANSCEND trial randomized 446…
-
New analysis: Four multicenter trials support primary use of drug-coated balloons over bare metal stents in femoropopliteal lesions
A patient-level, propensity-adjusted comparison of three-year results from a quartet of prospective, multicenter trials support the primary use of drug-coated balloons (DCBs) versus bare metal stents (BMS) in moderately complex femoropopliteal lesions, new data show. Lead researcher Mehdi Shishehbor, DO, revealed adjusted Kaplan-Meier estimates showing a 12-month primary patency of 90.4% for DCB vs. 80.9%…
-
‘Excellent’ three-year results presented for the BioMimics 3D stent in longer lesions
At the 2022 Vascular Interventional Advances (VIVA) meeting (Oct. 31–3 Nov. 3), Michael Lichtenberg, MD, from Arnsberg Clinic, Arnsberg, Germany, reported a subgroup analysis of the MIMICS-3D EU registry, revealing a headline finding of “excellent” three-year outcomes for the BioMimics 3D stent (Veryan Medical) in longer lesions. The presenter noted that the MIMICS-3D EU registry…
-
A recent snapshot of pediatric vascular trauma injuries
A study of major pediatric vascular injuries delivered in the Vascular and Endovascular Surgery Society (VESS) Paper Session during the 2022 Vascular Annual Meeting (VAM) in June found that 70.2% of the cohort analyzed presented with penetrating trauma. More specifically, noted authors Amanda Tullos, MD, a research fellow at Lousiana State University in New Orleans,…
-
Study: Combined antiplatelet, NOAC use linked to worse limb outcomes after suprainguinal bypass
A new analysis that found combined antiplatelet and novel oral anticoagulant (NOAC) therapy after suprainguinal bypass was associated with worse limb outcomes and equivalent survival compared to antiplatelet use alone has “weaknesses” but is “hypothesis-generating,” the senior author insisted during a scientific session at the 2022 annual meeting of the Midwestern Vascular Surgical Society (MVSS)…
-
TCAR has ‘tremendous appeal’ as alternative to transfemoral carotid artery stenting
This video is sponsored by Silk Road Medical. Richard Powell, MD, from Lebanon, New Hampshire, talks to Vascular Specialist at the Society for Vascular Surgery’s Vascular Annual Meeting (SVS VAM; June 15–18) in Boston about his initial interest in the transcarotid artery revascularization (TCAR) procedure, noting that the benefit of TCAR is that “we are…
-
arteriovenous fistula, arteriovenous graft, Dialysis access, disparities, Hemodialysis, Midwestern Vascular Surgical Society, MVSS, racial disparities, vascular access
MVSS 2022: Research on hemodialysis access surgery attracts inaugural Midwestern Vascular disparities award
The authors behind a new study that found “significant differences” in hemodialysis vascular access outcomes after first-time arteriovenous (AV) fistula or graft creation “directly related” to a patient’s race said the findings speak “to an injustice within the field of vascular surgery.” The research won the Midwestern Vascular Surgical Society’s inaugural MVSS Disparities Research Award at the organization’s 2022…
-
disparities, Diversity, IMG, Midwestern Vascular Surgical Society, MVSS, NESVS, New England Society for Vascular Surgery, Presidential address, Western Vascular Society, WVS
Regional vascular presidents measure state of specialty
Vincent Rowe, MD, and Raghu Motaganahalli, MD, delivered Presidential Addresses at the Western Vascular Society (WVS) and the Midwestern Vascular Surgical Society (MVSS) that spelled out ways in which vascular surgery can advance—and thrive. Rowe has been on the regional vascular meeting circuit this fall delivering invited guest lectures that drill down on the need…